Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALT 
Altimmune Inc (ALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ALT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 5 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.24% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 327.43M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 9 | Beta -0.01 | 52 Weeks Range 2.90 - 11.16 | Updated Date 08/29/2025 |
52 Weeks Range 2.90 - 11.16 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.31 | Actual -0.27 |
Profitability
Profit Margin - | Operating Margin (TTM) -458440% |
Management Effectiveness
Return on Assets (TTM) -32.43% | Return on Equity (TTM) -55.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 160178408 | Price to Sales(TTM) 16371.73 |
Enterprise Value 160178408 | Price to Sales(TTM) 16371.73 | ||
Enterprise Value to Revenue 8008.92 | Enterprise Value to EBITDA -4.2 | Shares Outstanding 88257296 | Shares Floating 87577672 |
Shares Outstanding 88257296 | Shares Floating 87577672 | ||
Percent Insiders 0.78 | Percent Institutions 43.29 |
Upturn AI SWOT
Altimmune Inc
Company Overview
History and Background
Altimmune Inc. was founded in 1997. Initially focused on developing intranasal vaccines, it has evolved to focus on developing treatments for obesity and liver diseases. Significant milestones include IND approvals for its drug candidates and clinical trial advancements.
Core Business Areas
- Obesity Therapeutics: Developing peptide-based therapeutics for the treatment of obesity, focusing on improving metabolic health and weight loss. Lead candidate is pemvidutide.
- Liver Diseases: Developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases, aiming to reduce liver inflammation and fibrosis.
Leadership and Structure
Dr. Vipin K. Garg serves as the President and CEO. The company has a Board of Directors that oversees its strategic direction and corporate governance. Altimmune is structured with functional departments focused on research and development, clinical operations, and commercial planning.
Top Products and Market Share
Key Offerings
- Pemvidutide: A GLP-1 receptor agonist and glucagon receptor agonist in clinical development for the treatment of obesity and NASH. It is in Phase 2 clinical trials for obesity. Competitors include Novo Nordisk (NVO) with Wegovy and Ozempic, Eli Lilly (LLY) with Mounjaro, and other companies developing GLP-1 based therapeutics.
- HepTcell: An immunotherapeutic for chronic hepatitis B. The drug candidate aims to achieve a functional cure for hepatitis B. It is in Phase 1/2 clinical trials. Competitors include companies such as Vir Biotechnology (VIR) and Arbutus Biopharma Corporation (ABUS) developing HBV therapeutics.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The obesity and NASH markets are experiencing significant growth due to increasing prevalence of these conditions and limited treatment options.
Positioning
Altimmune Inc. is a clinical-stage biopharmaceutical company. Its competitive advantage lies in its differentiated drug candidates and focus on areas of high unmet medical need.
Total Addressable Market (TAM)
The obesity market is projected to reach hundreds of billions of dollars by 2030. The NASH market is expected to reach tens of billions of dollars within the same timeframe. Altimmune is positioned to capture a share of these markets with successful clinical development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in clinical development
- Experienced management team
- Strong intellectual property portfolio
- Focus on high unmet medical needs
Weaknesses
- Reliance on clinical trial success
- Limited commercial infrastructure
- Significant financing requirements
- High regulatory risk
Opportunities
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing awareness of obesity and NASH
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- NVO
- LLY
- VIR
- GILD
Competitive Landscape
Altimmune faces significant competition from larger, established pharmaceutical companies. Its competitive advantage lies in its innovative drug candidates and focus on unmet medical needs. The GLP-1 market is highly competitive and there will be new entrants in the coming years. Altimmune will need to prove the safety and efficacy of pemvidutide to establish a strong market position.
Growth Trajectory and Initiatives
Historical Growth: The growth trajectory depends on success of clinical trials and ability to partner. There will be times when the stock price increases due to perceived success of clinical trials and it decreases when setbacks occur.
Future Projections: Analyst estimates vary, but the success of pemvidutide in Phase 2 trials has boosted estimates. Future growth is dependent on regulatory approval of drug candidates and successful commercialization.
Recent Initiatives: Focus on advancing pemvidutide clinical trials, securing partnerships for clinical development, and exploring new therapeutic areas.
Summary
Altimmune is a clinical-stage company focused on obesity and liver diseases, showing promise with pemvidutide. It faces high regulatory and financial risks due to reliance on clinical trial outcomes and the need for additional funding. Success hinges on positive clinical trial data, strategic partnerships, and navigating the competitive pharmaceutical landscape. Recent advancements with pemvidutide suggest potential, but significant challenges remain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and based on available information and may not reflect real-time accuracy.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Altimmune Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2005-10-06 | President, CEO & Director Dr. Vipin K. Garg Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://altimmune.com |
Full time employees 59 | Website https://altimmune.com | ||
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.